Is TB-500 the same as Thymosin Beta-4?

No. Thymosin Beta-4 (Tβ4) is the complete natural 43-amino-acid protein; TB-500 is a shorter synthetic peptide fragment that reproduces its actin-binding motif (LKKTET) but is a distinct chemical molecule. They share an actin-binding mechanism, not identity. They are often sold as interchangeable, which is inaccurate.

Why do many people treat them as synonyms?

Because TB-500 derives from Tβ4 and keeps its active actin-binding region, and because the most striking preclinical evidence comes from studies on full-length Tβ4 that is commercially attributed to the fragment. That genuine closeness is what makes the names blend together in shops and forums, even though the molecules are not identical.

Can they be told apart analytically?

Yes. Because they differ in size and sequence, they differ in molecular mass and analytical profile, so techniques such as HPLC and mass spectrometry distinguish them. That is why an independent Certificate of Analysis should specify whether the material is full-length 43-amino-acid Tβ4 or the TB-500 fragment. Both are research substances not approved for human use and prohibited in sport by WADA; this answer is educational, not medical advice.

← Guides

TB-500 vs Thymosin Beta-4: why they are not the same

You will often read that 'TB-500 is the same as Thymosin Beta-4', or see both names used as synonyms in shops and forums. That is not accurate. Thymosin Beta-4 (Tβ4) is a complete, naturally occurring 43-amino-acid protein present in almost every mammalian cell; TB-500 is a shorter synthetic peptide fragment that shares part of the sequence and some actin-binding mechanisms, but is a distinct chemical molecule. This guide clears up the confusion at an educational level: what each one is, why their names get mixed up, and how they actually differ. It is not medical advice and includes no dosing; both are research-use-only (RUO) substances not approved for human use in most jurisdictions.

What Thymosin Beta-4 (Tβ4) is

Thymosin Beta-4 is an endogenous peptide of 43 amino acids and roughly 5 kDa, present naturally in almost all human and animal cells. It is the principal G-actin-sequestering molecule (monomeric actin) in mammalian cells: it buffers the actin pool that governs cytoskeletal assembly and cell motility. Preclinical literature also describes it as a pleiotropic 'moonlighting' peptide linked to endothelial-cell migration, angiogenesis, and anti-inflammatory and cell-survival signalling. In short, it is a complete, well-characterised natural protein, studied mostly in defined pharmaceutical formulations.

What TB-500 is

TB-500 is marketed as a synthetic version of a fragment of Tβ4, not the whole protein. It corresponds to a partial sequence containing the central actin-binding motif (the LKKTET region, around amino acids 17-23), synthesised in the lab as a shorter, analytically defined molecule. It shares the actin-binding mechanism with Tβ4, but is a different chemical entity. Most published mechanistic work was done with full-length Tβ4, not with this fragment, so extrapolating from one to the other is not fully established.

Why they get confused

The confusion has a real basis: TB-500 derives from Tβ4 and reproduces its actin-binding motif, so gray-market sellers use both names as if they were the same product. On top of that, much of the appealing evidence (wound healing, angiogenesis, cardiac repair) comes from studies on full-length Tβ4, and that evidence is commercially 'lent' to the fragment. The practical result is that material labelled as one may be the other: full-length Tβ4 is sometimes substituted with the cheaper-to-synthesise TB-500 fragment, without the label making it clear.

How they differ: size, sequence and identity

The core difference is fragment versus complete protein. Tβ4 is 43 amino acids (~5 kDa), a full chain with multiple functional domains; TB-500 is a much shorter partial sequence centred on the LKKTET motif. They share the actin-binding site but differ in molecular mass, in the rest of the sequence and therefore in their analytical profile: a mass spectrometry (MS) analysis distinguishes one molecule from the other unambiguously. That is why, when verifying identity, a Certificate of Analysis should confirm whether the vial contains the full 43-amino-acid sequence or only the fragment.

Frequently asked questions

Is TB-500 the same as Thymosin Beta-4?: No. Thymosin Beta-4 (Tβ4) is the complete natural 43-amino-acid protein; TB-500 is a shorter synthetic peptide fragment that reproduces its actin-binding motif (LKKTET) but is a distinct chemical molecule. They share an actin-binding mechanism, not identity. They are often sold as interchangeable, which is inaccurate.
Why do many people treat them as synonyms?: Because TB-500 derives from Tβ4 and keeps its active actin-binding region, and because the most striking preclinical evidence comes from studies on full-length Tβ4 that is commercially attributed to the fragment. That genuine closeness is what makes the names blend together in shops and forums, even though the molecules are not identical.
Can they be told apart analytically?: Yes. Because they differ in size and sequence, they differ in molecular mass and analytical profile, so techniques such as HPLC and mass spectrometry distinguish them. That is why an independent Certificate of Analysis should specify whether the material is full-length 43-amino-acid Tβ4 or the TB-500 fragment. Both are research substances not approved for human use and prohibited in sport by WADA; this answer is educational, not medical advice.

This guide is an excerpt of the educational approach of Master of Peptides. The full master's includes the cited encyclopedia, practical tools, exam and certificate.

See the master's →

✓ Last reviewed · 2026-07-22